Pradaxa is ‘promising drug with a flaw’

Posted by Sarah Showard | Nov 07, 2012 | 0 Comments


A New York Times article chronicles the history of the anticoagulant drug Pradaxa, issued by Boehringer Ingelheim as an alternative to warfarin (brand name: Coumadin). According to the article, “A Promising Drug With a Flaw,” “Pradaxa is an example, some critics say, of what can happen when a drug that performs well in tightly controlled trials is released into the messy world of real-life medicine.”

Questions of Pradaxa's safety arose as quickly as it hit the market in late 2010. In 2011, Pradaxa was linked to more than 500 patient deaths reported to the FDA and to more injuries or deaths than 800-plus drugs monitored by the Institute for Safe Medication Practices, according to the Times article.

Further reading:

About the Author

Sarah Showard

Sarah Showard graduated from the University of Maryland in 1985, Magna Cum Laude with a Bachelor of Arts in English-Linguistics and a Certification in Womens Studies. She then graduated from New York University School of Law in 1988. Sarah began practice initially as an insurance defense attorne...


There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Showard Law Firm-Tucson's Local Law Firm for defective drug & medical device claims.

Showard 20staff 202017 201026 20special 20edit edit.jpg 20small

Showard Law Firm is dedicated to compassionate representation for our clients who have been injured by defective products, dangerous drugs or the negligence of any individual or company. We are experienced in litigation and ready to ensure you receive the maximum possible settlement for your injuries, medical bills, mental anguish and other losses.

Sarah Showard and Dr. Peter Ott - 2018 Heart Ball Chairs


Sarah and Peter are the proud chairs of this year's Heart and Stroke Ball, held on 2/17/18 at the El Conquistador. With a western theme "Heart of the West", this important fund raiser is in its 60th year, all raising funds to help with research and advances in the case against heart disease in the Tucson community.